Cosmetic compositions to improve the skin's barrier function

Abstract

Cosmetic compositions for improving the barrier function of the skin The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one microorganism of the genus Bifidobacterium and / or one of its fractions and / or one of its metabolites, at least one yeast extract of the genus Saccharomyces, at least one monosaccharide, preferably mannose or rhamnose, at least one gluco-oligosaccharide (GOS), at least one fructo-oligosaccharide (FOS), at least one beta-glucan and / or its derivatives and / or its salts such as sodium carboxymethyl beta-glucan, at least glycyrrhizic acid and / or its salts such as dipotassium glycyrrhizate, and at least hyaluronic acid and / or its salts.It also relates to the use of said cosmetic composition for skin care, preferably for improving the barrier function, as well as a cosmetic treatment method for skin care, in particular for improving the barrier function, comprising the application of said composition. Figure for abstract: none.

Description

Title of the invention: Cosmetic compositions for improving the barrier function of the skin

[0001] The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one microorganism of the genus Bifido-bacterium and / or one of its fractions and / or one of its metabolites, at least one yeast extract of the genus Saccharomyces, at least one monosaccharide, preferably mannose or rhamnose, at least one gluco-oligosaccharide (GOS), at least one fructo-oligosaccharide (FOS), at least one beta-glucan and / or its derivatives and / or its salts such as sodium carboxymethyl beta-glucan, at least one glycyrrhizic acid and / or its salts such as dipotassium glycyrrhizate, and at least one hyaluronic acid and / or its salts. It also relates to the use of said cosmetic composition for skin care, preferably for improving the barrier function, as well as a cosmetic treatment method for skin care, in particular for improving the barrier function, comprising the application of said composition.

[0002] The skin is the body's first barrier to the external environment. Human skin is made up of several compartments, three of which cover the entire body, namely a superficial compartment, the epidermis, the dermis, and a deep compartment, the hypodermis.

[0003] The natural human epidermis is composed mainly of three types of cells: keratinocytes, which are the vast majority, melanocytes and Langerhans cells. Each of these cell types contributes through its own functions to the essential role played in the body by the skin, in particular the role of protecting the body from external aggressions, which is called the "barrier function".

[0004] The epidermis is conventionally divided into a basal layer of keratinocytes constituting the germinative layer of the epidermis, a so-called spinous layer consisting of several layers of polyhedral cells arranged on the germinative layers, one to three so-called granular layers and finally the horny layer (or stratum corneum), consisting of a set of layers of keratinocytes at the terminal stage of their differentiation called comeocytes.

[0005] The cohesion of the epidermis as a water barrier is ensured by tight junctions between keratinocytes. These tight junctions are made up of transmembrane proteins such as occludin (OCL) and are located in the granular layer.

[0006] Strengthening the quality of the epidermis by favoring intracellular junctions and the cohesion of the horny layer contributes to maintaining the functions of the epidermis, to a good hydration.

[0007] Certainly, active ingredients have already been reported for their ability to act on the barrier function of the skin, as reported in EP 1333803 Bl.

[0008] However, in view of the prior art, there remains a need to reinforce, in particular in a natural way, the quality of the epidermis by favoring the intracellular junctions and the cohesion of the horny layer, which are a basic element making it possible to maintain the functions of the epidermis, good hydration.

[0009] Surprisingly, the inventors have demonstrated that a particular combination of active ingredients increases the expression of epidermal cohesion markers (occludin) by human keratinocytes and makes it possible to strengthen the skin barrier and improve skin hydration, improve the radiance and softness of the skin, and prevent the appearance of fine lines.

[0010] Thus, the present invention provides new cosmetic compositions capable of strengthening the skin barrier, more particularly via increasing the expression of epidermal cohesion markers (by improving the expression of occludin). Summary of the invention

[0011] The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium: - at least one microorganism of the genus Bifidobacterium and / or one of its fractions and / or one of its metabolites, - at least one yeast extract of the genus Saccharomyces, - at least one monosaccharide, preferably mannose or rhamnose, - at least one gluco-oligosaccharide (GOS), - at least one fructo-oligosaccharide (FOS), - at least one beta-glucan and / or its derivatives and / or its salts such as sodium carboxymethyl beta-glucan, - at least glycyrrhizic acid and / or its salts such as dipotassium gly-cyrrhizate, and - at least hyaluronic acid and / or its salts.

[0012] It also relates to the use of a cosmetic composition according to the invention for skin care, preferably to improve the barrier function.

[0013] It also relates to a cosmetic treatment method for skin care, in particular for improving the barrier function, comprising the application of a cosmetic composition according to the invention. Definitions

[0014] The term “composition comprising a physiologically acceptable medium” means a composition comprising a skin-compatible medium.

[0015] By "the skin" is meant the entire skin of the human body, and preferably, the skin of the face, the skin of the scalp, the décolleté, the neck, the arms and forearms, or even more preferably, the skin of the face, in particular the forehead, nose, cheeks, chin, and around the eyes.

[0016] By “at least one” we mean one or more by example 1, 2, 3, etc. Detailed description

[0017] Microorganism of the genus Bifidobacterium and / or one of its fractions and / or one of its metabolites

[0018] The composition according to the invention comprises at least one microorganism of the genus Bifidobacterium and / or one of its fractions and / or one of its metabolites.

[0019] The microorganisms of the genus Bifidobacterium used in the composition according to the invention are generally used in the form of a lysate.

[0020] A lysate commonly refers to a material obtained following the destruction or dissolution of biological cells by a phenomenon called cell lysis, thus causing the release of intracellular biological constituents naturally contained in the cells of the microorganism in question.

[0021] For the purposes of the present invention, the term lysate is used indifferently to designate the entire lysate obtained by lysis of the microorganism concerned or only a fraction of it.

[0022] The lysate used is therefore formed in whole or in part from intracellular biological constituents and constituents of cell walls and membranes.

[0023] More specifically, it contains the cellular cytoplasmic fraction containing enzymes such as lactic acid dehydrogenase, phosphatases, phosphoketolases, transaldolases and metabolites. By way of illustration, the constituents of cell walls are in particular peptidoglycan, murein or mucopeptide and teichoic acid and the constituents of cell membranes are composed of glycerophospholipids.

[0024] This cell lysis can be accomplished by different technologies, such as for example osmotic shock, thermal shock, by ultrasound, or even under mechanical stress such as centrifugation for example.

[0025] More particularly, this lysate can be obtained according to the technology described in US patent 4,464,362 and in particular according to the following protocol.

[0026] The microorganism considered of the Bifidobacterium type is cultivated anaerobically in a suitable culture medium, for example according to the conditions described in documents US 4,464,362 and EP 43,128. When the stationary phase of development is reached, the culture medium can be inactivated by pasteurization, by example at a temperature of 60 to 65 °C for 30 minutes. The microorganisms are then collected by a conventional separation technique, for example membrane filtration, centrifugation and resuspended in sterile physiological NaCl solution.

[0027] The lysate can be obtained by ultrasonic disintegration of such a medium in order to release the cytoplasmic fractions, cell wall fragments and metabolic products. Then all the components in their natural distribution are then stabilized in a weakly acidic aqueous solution.

[0028] A concentration of the order of 0.1 to 50%, in particular 1 to 20% and notably approximately 5% by weight of active material(s) relative to the total weight of the lysate is thus generally obtained.

[0029] The lysate can be used in different forms, in the form of a solution or in a powder form.

[0030] The microorganism belonging to the genus Bifidobacterium is more particularly chosen from the species: Bifidobacterium longum Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis or Bifidobacterium pseudocatenulatum and their mixtures.

[0031] Particularly suitable for the invention is the species Bifidobacterium longum.

[0032] For the purposes of the invention, the term metabolite designates any substance resulting from the metabolism of the microorganisms considered according to the invention and also having an effectiveness in strengthening the skin barrier and / or improving the hydration of the skin, improving the radiance and softness of the skin, and / or preventing the appearance of fine lines.

[0033] For the purposes of the invention, the term fraction more particularly designates a fragment of said microorganism having an effectiveness in strengthening the skin barrier and / or improving the hydration of the skin, improving the radiance and softness of the skin, and / or preventing the appearance of fine lines, by analogy with said whole microorganism.

[0034] The product marketed under the name Repair Complex CLR® by the company K. RICHTER GmbH and which is formed from an inactivated lysate of the species Bifidobacterium longum, falls within the scope of the invention.

[0035] Said at least one microorganism of the genus Bifidobacterium and / or one of its fractions and / or one of its metabolites may be present in the composition according to the invention in a content ranging from 0.0001% to 25% (expressed in dry weight), preferably in a content ranging from 0.001% to 20% and more preferably in a content ranging from 0.01% to 15% by weight relative to the total weight of the support or the composition. Yeast extract of the genus Saccharomyces

[0036] The composition according to the invention comprises at least one yeast extract of the genus Saccharomyces.

[0037] The yeasts can be prepared by culture in a conventional yeast culture medium (yeast extract: 10g / l, pepsin peptone: 7g / l, glucose: 20g / l, water: QSP).

[0038] An aqueous yeast extract will preferably be chosen, that is to say a yeast extract which, subject to the inevitable losses according to good manufacturing practices, contains all the water-soluble constituents of yeasts after lysis of the yeasts and removal by filtration of their membrane debris. This aqueous yeast extract will preferably be put back into solution.

[0039] Preferably, the aqueous extract of yeast of the genus Saccharomyces according to the invention will be prepared by solubilizing in water (preferably distilled water) whole yeasts of the genus Saccharomyces, by subjecting the suspension thus obtained to protein hydrolysis, by separating the soluble and insoluble phases of the solution obtained following this hydrolysis and by subjecting the soluble phase, recovered at the end of the previous step, to sterilization.

[0040] In a preferred embodiment of the invention, the aqueous yeast extract thus obtained can then optionally be dried and provided in powder form. The extract, preferably in powder form, can also be put into solution (this will then be referred to as yeast extract in solution), in particular a hydroalcoholic solution and preferably a hydroglycolic solution (for example a solution consisting of a mixture of water and pentylene glycol). In this solution, the aqueous yeast extract will preferably be added at a concentration between 0.5 and 8%, preferably between 2 and 7%, even more preferably between 3 and 5%.

[0041] The yeast extract used in the present invention will ultimately comprise at least 50%, preferably at least 60%, even more preferably at least 70% or at least 80% of water relative to its total weight.

[0042] Advantageously, the yeast extract in solution, usable according to the present invention, will have the following characteristics:

[0043] - It will have a pH between 5 and 8, preferably between 6 and 7. - It will include between 20 and 60 g of sugars per liter of solution (g / 1), preferably between 20 and 50 g / 1 and even more preferably between 25 and 35 g / 1 and / or, - It will have a dry matter concentration of between 10 and 60 g / l, preferably between 20 and 50 g / l and even more preferably between 37 and 47 g / l.

[0044] The population of whole yeasts used to prepare this aqueous yeast extract, i.e. before hydrolysis and / or sterilization, will preferably be 10E5 to 10e 10 colonies forming unit per milliliter (or cfu / ml) of aqueous yeast solution.

[0045] The aqueous yeast extract will preferentially have the characteristics following: - it will have a total nitrogen rate (according to the Kjeldahl method) of 5 to 15%, preferably 6 to 12%, even more preferably 7 to 10% and / or, - it will have a total free amino acid content (according to the Sôrensen method) of 2 to 10%, preferably 3 to 7%, even more preferably 4 to 6%, and / or, - it will have an Assimilable amino nitrogen / Total nitrogen ratio of 0.4 to 0.7%, preferably 0.4 to 0.6%, even more preferably 0.5 to 0.6%.

[0046] Protein hydrolysis will preferably be carried out by chemical or acid hydrolysis or by using natural yeast enzymes and will preferably be carried out for at least 60%, preferably at least 80%, even more preferably at least 90% of all the proteins present in the yeast solution after lysis of the yeasts.

[0047] The separation of the soluble and insoluble phases obtained following the hydrolysis of the proteins will be carried out by any means known to those skilled in the art depending on the nature of the extract sought. This phase separation can for example be carried out by filtration, decantation or centrifugation, filtration being the preferred means. Following this separation of the soluble and insoluble phases, the soluble phase is recovered.

[0048] Sterilization may be carried out by any means known to those skilled in the art and in particular by sterilizing filtration. The latter will preferably be carried out by the use of a membrane filter whose pore size is chosen according to the size of the membrane elements that it is desired to eliminate. This technique is well known to those skilled in the art.

[0049] Following this sterilization step, the aqueous yeast extract obtained can be dried to provide it in powder form. This drying can also be carried out by any means known to those skilled in the art, for example by evaporation, lyophilization or by atomization.

[0050] In the Saccharomyces genus, the following species can be cited: Sac-charomyces bailii, Saccharomyces carlsbergensis, Saccharomyces uvarum, Saccharomyces cerevisiae, Saccharomyces delbrueckii, Saccharomyces exiguus, Saccharomyces fermentati, Saccharomyces florentinus, Saccharomyces fragilis, Saccharomyces fructuum, Saccharomyces heterogenicus, Saccharomyces oleaginosus, Saccharomyces rosei, Saccharomyces steineri, Saccharomyces boulardii, Saccharomyces kefir, Saccharomyces kluyveri.

[0051] Preferably, a yeast of the species Saccharomyces cerevisiae will be chosen.

[0052] Preferably, this extract does not include live yeast.

[0053] An example of an extract according to the invention is marketed by the company SILAB (BP 213, 19108 Brive Cedex France) under the name FIRMALIFT® GR. It comes in the form of a slightly opalescent, yellow solution containing 32.0 g / l

[0054]

[0055]

[0056]

[0057]

[0058]

[0059]

[0060]

[0061] of sugars. The CAS number of this extract is 8013-01-2. Its EINECS / ELINCS number is 232-387-9. This extract is at a concentration of 4.2% in a hydroglycolic solution comprising 7.5% pentylene glycol and 88.3% water. Preferably, said at least one yeast extract according to the invention will be used at a concentration of 0.0001% to 5%, preferably 0.0001% to 1% and even more preferably 0.0004% to 0.5% relative to the total weight of the composition. Monosaccharide The composition according to the invention comprises at least one monosaccharide, preferably mannose or rhamnose, By "monosaccharide" is meant a monosaccharide sugar comprising at least 5 carbon atoms of formula CX(H2O)X, with x being an integer greater than or equal to 5, preferably x is greater than or equal to 6, in particular x is inclusively between 5 and 7, preferably x = 6. They may be of D or L configuration, and of alpha or beta anomer, as well as one of their salts or their solvates such as hydrates. Generally, the monosaccharide can be used from 0.0001% to 20% by weight, preferably from 0.001% to 10% by weight, and most preferably from 0.002% to 5% by weight, relative to the total weight of the composition. In particular, in the context of the present invention, said at least one monosaccharide of the composition is mannose. Mannose is a monosaccharide made up of 6 carbons, it is a hexose. Its molecular formula is C6H12O6, the same as glucose, of which it is the C2 epimer (that is to say, its spatial configuration is rigorously the same, except for the substituent at carbon 2, where it is reversed compared to glucose). The mannose considered according to the invention corresponds to the following formula (I): [Chem.l] CFLOH .£ OH (D

[0062] Of course, the invention considers all the enantiomeric forms of mannose.

[0063] Mannose can also be present in solvated form (including hydrates) and in the form of a mixture of D and L stereoisomers: DL-Mannose.

[0064] According to a preferred embodiment, the monosaccharide Mannose is D-mannose of the following formula (II):

[0065] [Chem.2] ch2oh k OH OH^ OH^----OH (II)

[0066] D-mannose is naturally present in plants, particularly certain fruits including cranberries, or hardwood (beech, birch).

[0067] As an illustration of D-mannose suitable for the invention, mention may in particular be made of D-Mannose marketed by the company Danisco Sweeteners® or the company Symrise®.

[0068] Generally, the mannose monosaccharide can be used from 0.0001% to 20% by weight, preferably from 0.001% to 10% by weight, and most preferably from 0.002% to 5% by weight, relative to the total weight of the composition.

[0069] In one embodiment according to the invention, said at least one monosaccharide of the composition is rhamnose.

[0070] Rhamnose is a 6-deoxyhexose of the aldose type, it consists of a chain of 5 carbon elements as well as an aldehyde function. It can be classified either as a methyl-pentose or as a 6-deoxyhexose.

[0071] The rhamnose considered according to the invention has the following formula (III):

[0072] [Chem.3] (III)

[0073] Of course, the invention considers all the enantiomeric forms rhamnose.

[0074] Rhamnose can also be present in solvated form (including hydrates) and in the form of a mixture of D and L stereoisomers: DL-rhamnose.

[0075] According to a preferred embodiment, the rhamnose monosaccharide is L-rhamnose, in particular a monohydrated crystalline form, such as for example L-rhamnose monohydrate in crystalline form sold by the company Danisco®.

[0076] Generally speaking, the monosaccharide rhamnose can be implemented in

[0077] 0.0001% to 20% by weight, preferably 0.001% to 10% by weight, and most preferably potentially from 0.002% to 5% by weight, relative to the total weight of the composition.

[0078] In one embodiment of the present invention, the composition comprises a combination of mannose and rhamnose. Gluco-oligosaccharide (GOS)

[0079] The composition according to the invention comprises at least one gluco-oligosaccharide.

[0080] Gluco-oligosaccharides (GOS), or oligoglucans, are oligosaccharides consisting of a chain of glucose units linked at α1-6 and which may also contain α1-2, α1-3; α1-4 bonds. They are synthesized by a trans-glucosylation reaction catalyzed by enzymes of the glucan-sucrase family.

[0081] Preferably, the gluco-oligosaccharides are oligosaccharides consisting of a chain of glucose units linked at α1-6 and α1-2.

[0082] Advantageously, the number of glucose units is between 2 and 10, even better between 4 and 6, even more preferably the number of glucose units is 4.

[0083] In addition, gluco-oligosaccharides can be synthesized by the polymerization of glucose molecules, a reaction catalyzed by a specific enzyme of the glyco-syltransferase type, extracted and purified from a bacterial strain of Leuconostoc me-senteroides. This reaction requires the use of an acceptor: maltose (Glucose-Glucose) but also of a glucose donor: sucrose (Glucose-Fructose).

[0084] In a preferred embodiment, the gluco-oligosaccharides (GOS) are of the following formula (IV):

[0085] [Chem.4] QZ year (IV)

[0086] Among the usable and commercially available GOS, we can cite Bioecolia® from Solabia.

[0087] Preferably, said at least one GOS according to the invention will be used at a concentration of 0.0001% to 5%, preferably of 0.0002% to 2% and even more preferably of 0.0005% to 1% relative to the total weight of the composition. Fructo-oligosaccharide (FOS)

[0088] The composition according to the invention comprises at least one fructo-oligosaccharide (FOS).

[0089] Fructo-oligosaccharides (or FOS) also called oligofructoses or oligo-fructans are short chains of fructose linked together by bonds [31-2.

[0090] Fructo-oligosaccharides (or FOS) correspond to the general formula (V): G(F)n where G is a glucose unit, F is fructose and n varies from 1 to 10.

[0091] [Chem.5] (V)

[0092] Fructo-oligosaccharides (FOS) are produced:

[0093] - by partial enzymatic hydrolysis of inulin (eg: Raftilose® of Orafti-Belgium), or

[0094] - by enzymatic synthesis from sucrose (eg: Actilight® from Beghin Meiiji industries-France), or

[0095] - by extraction from Yacon or jicama (Polymnia sonchifolia, synonym: Smallanthus sonchifolia), in particular the extraction is carried out in the absence of solvent, by cold pressing of Yacon tubers.

[0096] The FOS used in the invention may be a mixture of FOS. In particular, mention may be made of GF2 + GF3 + GF4 mixtures such as Quantom FOS95 from Quantum hi-Tech or Actilight® from Beghin Meiiji industries-France, the latter corresponding to a mixture of GF2 37%, GF3 53% and GF4 10%.

[0097] Preferably, said at least one FOS according to the invention will be used at a concentration of 0.00001% to 1%, preferably of 0.00002% to 0.5% and even more preferably of 0.00003% to 0.1% relative to the total weight of the composition.

[0098] Advantageously, the mass ratio [GOS / FOS] is at least 2, preferably between 2 and 4, even better between 3 and 4.

[0099] In particular, said at least one gluco-oligosaccharide (GOS) and said at least one fructo-oligosaccharide (FOS) may be used in the form of a mixture marketed under the name Ecoskin® by Solabia.

[0100] Advantageously, the composition according to the invention may further comprise at least one probiotic microorganism.

[0101] For the purposes of the present invention, the term "probiotic microorganism" means a living microorganism which, when consumed in adequate quantities, has a positive effect on the health of its host "joint FAO / WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotic in Food Including Powder Milk with Live Lactic Acid Bacteria, October 6, 2001", and which can in particular improve the intestinal microbial balance.

[0102] In the case of the skin said probiotic microorganism is a probiotic microorganism, which, when applied to the skin in adequate quantity, has a positive effect on the aesthetic qualities of the skin and mucous membranes.

[0103] More particularly, these are probiotic microorganisms from the group of lactic acid bacteria, such as Lactobacillus. As an illustration of these lactic acid bacteria, mention may be made more particularly of Lactobacillus casei, Lactobacillus acidophilus and their mixtures.

[0104] Specific examples of probiotic microorganisms are. Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus curvatus, Lactobacillus delbruckii subsp. Lactis, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus casei, Lactobacillus rhamnosus (Lactobacillus GG), Lactobacillus sake, Lactococcus lactis, Streptococcus thermophilus, Lactobacillus acidophilus, L. del-brueckii, L. helveticus, L. salivarius, L. curvatus, L. plantarum, L. sakei, L. brevis, L. buchneri, L. fermentum, L. reuteri, Lactobacillus bulgaricus, Lactobacillus longum, Lactobacillus lactis, bifidobacterium longum and their mixtures.

[0105] Advantageously, the probiotic microorganism is present in the composition according to the invention in a concentration of between 0.00001% and 1% by weight, preferably between 0.00001% and 0.1% by weight, even more preferably between 0.00001% and 0.01% by weight relative to the total weight of the composition.

[0106] The microorganism(s) may be included in a composition according to the invention in a living, semi-active or inactivated, dead form.

[0107] It(they) may also be included in the form of fractions of cellular components or in the form of metabolites. The microorganism(s), metabolite(s) or fraction(s) may also be introduced in the form of a lyophilized powder, a culture supernatant and / or where appropriate in a concentrated form.

[0108] According to a preferred embodiment of the invention, these microorganisms are in an inactivated form, in particular by heat or high pressure.

[0109] The terms “in inactivated form”, “in non-revivable form” and “in dead form” are synonymous here.

[0110] Bacteria in “semi-active form” are bacteria which have partially or totally lost their proliferation properties.

[0111] In the case where the microorganisms are formulated in a composition in a living form, the quantity of living microorganisms can vary from 103 to 1015 cfu / g, in particular from 105 to 1015 cfu / g and more particularly from 107 to 1012 cfu / g of microorganisms per gram of composition.

[0112] In a particularly preferred embodiment, the composition according to the invention further comprises at least one probiotic microorganism chosen from bacteria of the genus Lactobacillus, in particular Lactobacillus casei, Lactobacillus acidophilus and their mixtures, in a content of between 0.00001% and 1% by weight, preferably between 0.00001% and 0.1% by weight, even more preferably between 0.00001% and 0.01% by weight relative to the total weight of the composition.

[0113] In particular, said at least one gluco-oligosaccharide (GOS), and said at least one fructo-oligosaccharide (FOS), and said at least one probiotic microorganism may be used in the form of a mixture comprising 70% by weight of gluco-oligosaccharide (GOS), 19% by weight of Polymnia sonchifolia tuber juice (including at least 20% by weight of FOS), 1% by weight of Lactobacillus acidophilus and Lactobacillus casei, 10% by weight of maltodextrin. Beta-glucan and / or its derivatives and / or its salts

[0114] The composition according to the invention comprises at least one beta-glucan and / or its derivatives and / or its salts such as sodium carboxymethyl beta-glucan.

[0115] For the purposes of the present invention, the term “beta-glucan derivatives” means a beta-glucan which has undergone chemical modifications, preferably by carboxymethylation.

[0116] “Salt” means a salt formed by an inorganic or organic base.

[0117] Examples of basic salts include alkali metal hydroxides such as sodium, potassium and lithium; alkaline earth metal hydroxides such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc. Preferably a base salt is a sodium or magnesium salt. These compounds are well known to those skilled in the art and are described in applications EP0819762 and US6986903.

[0118] These compounds are polysaccharides consisting entirely of D-glucose linked by beta bonds.

[0119] They are produced from baker's yeast and are soluble in water.

[0120] Beta-glucan has the formula (VI) below:

[0121] [Chem.6] (VI)

[0122] Sodium carboxymethyl beta-glucan is the sodium salt of the carboxymethyl ether of beta-glucan.

[0123] As an illustration of beta-glucan and / or its derivatives and / or its salts suitable for the invention, mention may in particular be made of sodium carboxymethyl beta-glucan CM-Glucan Granulate® from the company Mibelle AG Biochemistry® or magnesium carboxymethyl beta-glucan CM Glucan Forte® from the company Mibelle AG Biochemistry®. Preferably, the beta-glucan and / or its derivatives and / or its salts such as sodium carboxymethyl beta-glucan according to the invention will be used at a concentration of 0.0001% to 1%, preferably of 0.0002% to 0.5% and even more preferably of 0.0003% to 0.3% relative to the total weight of the composition. Glycyrrhizic acid and / or its salts

[0124] The composition according to the invention comprises at least glycyrrhizic acid and / or its salts such as dipotassium glycyrrhizate.

[0125] The term "salt" means a salt formed by an inorganic or organic base. Examples of salts that may be mentioned are the ammonium salt of glycyrrhizic acid and dipotassium glycyrrhizate. Preferably, the salt of glycyrrhizic acid according to the invention is dipotassium glycyrrhizate.

[0126] Glycyrrhizic acid or (3[3,20[3)-20-carboxy-l l-oxo-30-norolean-12-en-3-yl 2-O-[3-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid is a heteroside, the aglycone part of which (an acidic terpene) is linked to a dimeric acidic ose of glucuronic acid.

[0127] It corresponds to formula (VII) below:

[0128] [Chem.7] drunk (VII)

[0129] Dipotassium glycyrrhizate has the formula (VIII) below:

[0130] [Chem. 8] (VIII)

[0131] Preferably, glycyrrhizic acid and / or its salts such as dipotassium glycyrrhizate according to the invention will be used at a concentration of 0.0001% to 2%, preferably 0.0002% to 1.5% and even more preferably 0.0003% to 1% relative to the total weight of the composition. Hyaluronic acid and / or its salts

[0132] The composition according to the invention comprises at least hyaluronic acid and / or its salts.

[0133] Hyaluronic acid belongs to the family of glycosaminoglycans (GAGs).

[0134] GAGs are linear chains composed of the repetition of a basic diholoside always containing a hexosamine (glucosamine or galactosamine) and another ose (glucuronic acid, iduronic acid or galactose). Glucosamine is either N-sulfated or N-acetylated. In contrast, galactosamine is always N-acetylated. In addition, there may be sulfates O-linked to hexosamine, uronic acid and galactose.

[0135] Hyaluronic acid or hyaluronan (HA) is the main GAG of the dermis, the latter containing half of the body's HA.

[0136] It is a polysaccharide of disaccharides themselves composed of D-glucuronic acid and N-acetylglucosamine, linked together by alternating beta-1,4 and beta-1,3 glycosidic bonds. It plays an important role in the hydration and elasticity of the skin.

[0137] The composition according to the invention comprises at least 0.35% by weight of hyaluronic acid or one of its salts, or their mixtures, relative to the total weight of the composition.

[0138] As hyaluronic acid salts, mention may in particular be made of potassium hyaluronate and sodium hyaluronate.

[0139] Preferably, sodium hyaluronate will be used according to the invention.

[0140] In particular, sodium hyaluronate with a molecular weight of 1,100,000 Daltons marketed by the company SOLIANCE under the name CRISTALHYAL® may be used in the composition of the invention.

[0141] Hyaluronic acid or one of its salts, or mixtures thereof may be present in the composition according to the invention in an amount of at least 0.0001% by weight (of dry matter), preferably at least 0.0002% by weight (of dry matter), relative to the total weight of the composition. In a preferred embodiment, hyaluronic acid or one of its salts, or mixtures thereof may be present in the composition according to the invention in an amount ranging from 0.0001% to 2% by weight (of dry matter) relative to the total weight of the composition, preferably ranging from 0.0002% to 1.5% by weight (of dry matter), even better ranging from 0.0003% to 1% by weight (of dry matter) relative to the total weight of the composition.

[0142] As mentioned previously, the composition according to the invention comprises a physiologically acceptable medium. More particularly, said physiologically acceptable medium may comprise water and / or one or more water-soluble organic solvents which may be chosen from linear or branched C1-C6 monoalcohols such as ethanol, isopropanol, tert-butanol or n- butanol; polyols such as glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol (or 2-methyl-2,4-pentanediol), and polyethylene glycols; polyol ethers such as dipropylene glycol monomethyl ether; and mixtures thereof.

[0143] Preferably, the composition according to the invention has a water content ranging from 20% to 95% by weight, even better from 40% to 90% by weight relative to the total weight of the composition.

[0144] Advantageously, the composition comprises one or more water-soluble organic solvents in a content ranging from 0.5% to 25% by weight, preferably from 5% to 20% by weight, even better from 10% to 15% by weight relative to the total weight of the composition. Dosage forms

[0145] A cosmetic composition according to the invention is in particular applied topically.

[0146] The compositions intended for external topical administration may be aqueous, hydroalcoholic or oily solutions, solutions or dispersions of the lotion or serum type, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or suspensions or emulsions, of soft, semi-solid or solid consistency, of the cream type, aqueous or anhydrous gels, microemulsions, microcapsules, microparticles, or vesicular dispersions of the ionic and / or non-ionic type.

[0147] These compositions are prepared according to the usual methods.

[0148] A topical composition according to the invention can advantageously be formulated in any galenic form suitable for skin care, in particular in the form of cleansing, protective, treatment or care creams for the face or body, masks to be left on the skin or hair, make-up removing milks, protective or care body milks, lotions, gels or mousses for skin care, such as cleansing lotions, bath compositions.

[0149] Alternatively, a topical composition according to the invention may advantageously be formulated in any galenic form suitable for hair care, in particular in the form of a hair lotion, a shampoo, in particular anti-dandruff, a conditioner, a detangler, a hair cream or gel, a treatment lotion, an anti-hair loss lotion or gel, an anti-parasitic shampoo, or a treatment shampoo, in particular anti-seborrheic, a scalp care product, in particular anti-irritant, anti-aging, restructuring. Adjuvants

[0150] In a known manner, the galenic forms dedicated to topical administration may also contain adjuvants customary in the cosmetic, pharmaceutical and / or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents other than those mentioned above, preservatives, antioxidants, solvents, perfumes, fillers, filters, fatty substances such as oils, emulsifiers, odor absorbers and coloring matters. The quantities of these different adjuvants are those conventionally used in the field considered, and for example from 0.01 to 20% of the total weight of the composition. These adjuvants, depending on their nature, may be introduced into the fatty phase and / or into the aqueous phase.

[0151] As hydrophilic gelling agents that can be used in the composition according to the invention, mention may be made of modified or unmodified carboxyvinyl polymers, such as the products marketed under the names Carbopol (INCI name: carbomer) and Pemulen (INCI name: Acrylates / C10-30 akyl acrylate crosspolymer) by the company Goodrich, or such as crosslinked sodium polyacrylate marketed under the name Cosmedia SP by the company Cognis (INCI name: Sodium polyacrylate); polyacrylamides; homopolymers of 2-acrylamido-2-methylpropane sulfonic acid such as the product marketed by Clariant under the name Hostacerin AMPS (INCI name: ammonium polyacryldimethyltaurate); crosslinked anionic copolymers of acrylamide and AMPS, in the form of an emulsion, such as those marketed under the name SEPIGEL 305 (CTFA name: Polyacrylamide C13-14 Iso-paraffin / Laureth-7) and under the name SIMULGEL 600 (CTFA name: Acrylamide / Sodium acryloyldimethyltaurate copolymer / Isohexadecane / Polysorbate 80) by the company SEPPIC; acrylate / acrylonitrile copolymers such as HYPAN SS201 marketed by the company Kingston; synthetic neutral polymers such as poly-N-vinylpyrrolidone; polysaccharides such as guar gum, xanthan gum and cellulose derivatives. The quantity of these polymers can range, for example, from 0.05 to 5% by weight and better still from 0.1 to 3% by weight relative to the total weight of the composition.

[0152] As lipophilic gelling agents, mention may be made of modified clays such as bentones, metallic salts of fatty acids such as aluminum stearates and hydrophobic silica, or even ethylcellulose and polyethylene.

[0153] When a composition of the invention is an emulsion, the proportion of the fatty phase can range from 0.5 to 80% by weight, and preferably from 1 to 50% by weight relative to the total weight of the composition. The oils, emulsifiers and co-emulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic field. The emulsifier and the co-emul may be present in the composition in a proportion ranging from 0.2 to 30% by weight, and preferably from 0.3 to 20% by weight relative to the total weight of the composition.

[0154] When the composition of the invention is an oily solution or gel, the fatty phase can represent more than 90% of the total weight of the composition.

[0155] Examples of oils that can be used include:

[0156] - hydrocarbon oils of vegetable origin, such as liquid triglycerides fatty acids containing 4 to 10 carbon atoms such as triglycerides of heptanoic or octanoic acids or, for example, sunflower, corn, soybean, pumpkin, grape seed, sesame, hazelnut, apricot, macadamia, arara, castor, avocado oils, triglycerides of caprylic / capric acids such as those sold by the company Stearineries Dubois or those sold under the names “Miglyol 810”, “812” and “818” by the company Dynamit Nobel, jojoba oil, shea butter oil;

[0157] - synthetic esters and ethers, in particular of fatty acids, such as oils of formulas R1COOR2 and R1OR2 in which RI represents the residue of a fatty acid containing from 8 to 29 carbon atoms, and R2 represents a hydrocarbon chain, branched or not, containing from 3 to 30 carbon atoms, such as for example Purcellin oil, isononyl isononanoate, isopropyl myristate, 2-ethylhexyl palmitate, 2-octyldodecyl stearate, 2-octyldodecyl erucate, isostearyl isostearate; hydroxylated esters such as isostearyl lactate, octylhydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate; fatty alcohol heptanoates, octanoates, decanoates; polyol esters, such as propylene glycol dioctanoate, neopentyl glycol diheptanoate and diethylene glycol diisononanoate; and pentaerythritol esters such as pentaerythrityl tetraisostearate;

[0158] - linear or branched hydrocarbons, of mineral or synthetic origin, such as paraffin oils, volatile or not, and their derivatives, petroleum jelly, polydecenes, hydrogenated polyisobutene such as parleam oil, fatty alcohols having from 8 to 26 carbon atoms, such as cetyl alcohol, stearyl alcohol and their mixture (cetylstearyl alcohol), octyldodecanol, 2-butyloctanol, 10 2-hexyldecanol, 2-undecylpentadecanol, oleyl alcohol or linoleyl alcohol; silicone oils such as volatile or non-volatile polymethylsiloxanes (PDMS) with a linear or cyclic silicone chain, liquid or pasty at room temperature, in particular cyclopolydhné-thylsiloxanes (cyclomethicones) such as cyclohexasiloxane; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups, pendant or at the end of the silicone chain, groups having from 2 to 24 carbon atoms; phenyl silicones such as phenyltrimethicones, phenyldimethicones, phenyltrime- ethylsiloxydiphenyl-siloxanes, diphenyl-dimethicones, diphenylmethyldiphenyl trisiloxanes, 2-phenylethyltrimethyl-siloxysilicates, and polymethylphenyl-siloxanes; and

[0159] - their mixtures.

[0160] In the list of oils cited above, the term “hydrocarbon oil” means any oil comprising mainly carbon and hydrogen atoms, and possibly ester, ether, fluorine, carboxylic acid and / or alcohol groups.

[0161] As emulsifiers, mention may be made of amphoteric, cationic, anionic or non-ionic surfactants, used alone or in a mixture, and possibly a co-emulsifier.

[0162] For O / W emulsions, examples of emulsifiers that may be mentioned include non-ionic emulsifiers such as oxyalkylenated (more particularly polyoxyethylenated) fatty acid and glycerol esters; oxyalkylenated (oxyethylenated and / or oxypropylenated) fatty acid esters; oxyalkylenated (oxyethylenated and / or oxypropylenated) fatty acid ethers; oxyalkylenated (oxyethylenated and / or oxypropylenated) fatty alcohol esters; sugar esters, in particular oxyalkylenated, phosphoric acid and fatty alcohol esters; and mixtures thereof.

[0163] In a preferred embodiment, the composition according to the invention further comprises at least one ingredient chosen from silicone fatty substances such as silicone oils, gums and waxes; non-silicone fatty substances such as oils, pastes and waxes of vegetable, mineral, animal and / or synthetic origin; fatty acids having from 8 to 32 carbon atoms; synthetic esters and ethers, in particular of formula R1COOR2 and R1OR2 in which RI represents the residue of a fatty acid comprising from 8 to 29 carbon atoms, and R2 represents a hydrocarbon chain, branched or not, containing from 3 to 30 carbon atoms; linear or branched hydrocarbons, of mineral or synthetic origin; fatty alcohols having from 8 to 26 carbon atoms; water; C2-C6 monoalcohols; glycols selected from propylene glycol, butylene glycol, pentylene glycol; ketones;thickeners, emulsifiers, surfactants, gelling agents, perfumes, fillers, coloring agents, moisturizers, vitamins, polymers.;

[0164] The quantities of these different ingredients are those conventionally used in the field considered, and for example from 0.01 to 20% of the total weight of the composition. Applications

[0165] The cosmetic compositions according to the invention may be facial or body care products.

[0166] The compositions according to the invention are cosmetic compositions intended for skin care.

[0167] These compositions are therefore intended to be applied to the skin.

[0168] Thus, according to one of these aspects, the present invention relates to the use of a cosmetic composition according to the invention, for skin care, preferably to improve the barrier function.

[0169] According to another of these aspects, the present invention also relates to a cosmetic process for skin care, preferably for improving the barrier function, comprising the application of a cosmetic composition according to the invention.

[0170] In particular, the composition according to the invention makes it possible to obtain a strengthening of the skin barrier, more particularly via the increase in the expression of epidermal cohesion markers (by increasing the expression of occludin).

[0171] The composition according to the invention can thus be used to improve the hydration of the skin, improve the radiance and softness of the skin, and / or prevent the appearance of fine lines.

[0172] The invention is now illustrated by the following examples. Examples INCI MP Names Trade Names Supplier Active Ingredient Concentration BIFIDA FERMENT LYSATE REPAIR COMPLEX CLR PE-F CLR Bifida ferment lysate 99.2% + acetic acid 0.15% + sodium benzoate 0.55% + lactic acid 0.1% FIRMALIFT GRV SILAB YEAST EXTRACT Yeast extract 4.2% + pentylene glycol 7.5% + water 88.3% ALPHA-GLUCAN OLIGOSACCHARI (and) POLYMNIA SON-CHIFOLIA ROOT JUICE (and) LACTOBACILLUS ECOSKIN LO SOLABIA ALPHA-GLUCAN OLIGOSACCHARI 70% + POLYMNIA SONCHIFOLIA ROOT JUICE 19% + LACTOBACILLUS 1% + maltodextrin 10% DI-POTASSIUM GLYCYRRHIZATE DIPOTASSIUM GLYCYRRHIZIN ATE MARUZEN 100% active ingredient MANNOSE D-MANNOSE SHIJIAZHUANG HUAXU PHAR-MACEUTICAL 100% active ingredient SODIUM HYALURONATE GENHYAL SOLIANCE (GIVAUDAN) 100% active ingredient CARBOXYMETH YL BETA-GLUCAN SODIUM CM-GLUCAN GRANULATE MIBELLE AG BIOCHEMISTRY 100% active ingredient

[0174] Raw Materials (MPs) / INCI Names / Suppliers / Concentration in the MP of active ingredient

[0175] NB: the raw materials tested in the in vitro tests were tested by weight of raw material and not by active ingredient.

[0176] A composition according to the invention is exemplified in Table 2 below:

[0177] [Tables2] INCI (US / EU) %Concentration ACTIVE INGREDIENTS 0.105 OIL 1.5 CHELATING AGENT qs. PRESERVATIVE qs. GLYCOLS 2.3 GLYCERIN 5 SODIUM HYALURONATE 0.4 HYDROPHILIC GELLING AGENT 0.35 BIFIDA FERMENTED LYSATE 10.1 YEAST EXTRACT 2.62 DIPOTASSIUM GLYCYRRHIZATE 0.2 SODIUM CARBOXYMETHYL BETA-GLUCAN 0.101 ALPHA-GLUCAN OLIGOSACCHARIDE (AND) POLYMNIA SON-CHIFOLIA ROOT JUICE (AND) LACTOBACILLUS 0.3 MANNOSE 0.5 FRAGRANCE qs. WATER qs. 100

[0178] Synergistic effect of the active ingredients of a composition according to the invention on the expression of epidermal cohesion markers

[0179] Different combinations of active ingredients are prepared as shown in Table 3 below. Name of the tested combination Active ingredients present Concentrations tested Mix 1 - BIFIDA FERMENT LYSATE - YEAST EXTRACT - ECOSKIN (FOS+GOS) (ALPHA-GLUCAN OLIGOSACCHARIDE (AND) POLYMNIA SON-CHIFOLIA ROOT JUICE (AND) LACTO-BACILLUS) - MANNOSE - SODIUM HYALURONATE 0.04% 0.011% 0.0012% 0.0021% 0.0015% Mix 2 - BIFIDA FERMENT LYSATE - YEAST EXTRACT - ECOSKIN (FOS+GOS) (ALPHA-GLUCAN OLIGOSACCHARIDE (AND) POLYMNIA SON-CHIFOLIA ROOT JUICE (AND) LACTO-BACILLUS) - MANNOSE - SODIUM HYALURONATE - DIPOTASSIUM GLYCYRRHIZATE 0.04% 0.011% 0.0012% 0.0021% 0.0015% 0.0008% Mix 3 - BIFIDA FERMENT LYSATE - YEAST EXTRACT - ECOSKIN (FOS+GOS) (ALPHA-GLUCAN OLIGOSACCHARIDE 0.04% 0.011% 0.0012% 0.0021% 0.0015% 0.0008% (AND) POLYMNIA SON-CHIFOLIA ROOT JUICE (AND) LACTO-BACILLUS) - MANNOSE - SODIUM HYALURONATE - DIPOTASSIUM GLYCYRRHIZATE - SODIUM CARBOXYMETHYL BETA-GLUCAN 0.004%

[0181] The results obtained, illustrated in particular by tables 4 and 5 below, demonstrate that the combination of the active ingredients of the composition according to the invention makes it possible to obtain an improved expression, in particular the synergy of effect of the active ingredients between them vs the use of only some of them. Test compound Concentration images Qcckidin (RAJ / Cefete) Mean tRFUrCaMe) Will be % Contf^e Will be pTV Control Q ml ! 1 MMM 04ÜÜ1 09 207 ©4 ISO 5 095 100 5 99 352 C&CI; 1.5 B -3 C-3 0-3 1 238 872 1298125 1304848 121 1470 129 255 1 625 547 Ferfida extract 0.041% B-8 C-5 3-5 11 122 12. thread 767 104 553 Yeast extract 0 0T1% E-7 C-7 O-7 : ,Ç; 023 117 504 111003 14 TÎ8 15 CW 385 83 481 Eceskin ( LUCANES OLIGOSACCHARIDE. C-9 DS 118 484 36 866 111 446 12 11-8 13 ns 670 129 068 Dipotassffira glycÿTrtiizaté E -4 F-4 G-4 77 112 109 12015 10 117 241 ■Mannose û,002:-o E-6 Fs G-6 92 134 SA 398 77 084 3 094 82 0 AS 74 721 HytaœnKjue 0 acid.0015% E-Ê FS G-8 103 977 104 774 100 939 3 453 107 4 ns 94SW S-Glucan 0.0004^ œ en en W L. © 162 393 1410755 900 138 033 . 'Test composed- Centaftsn images Occtttdm (RFWDe&itei Average<Rm / Cel§ùSe> Seffi % CüHdrôie Sera {%} Contract OO Ctj M K3 K< 241147 332 429 231 1S1 253 255 t ' l O *) cj r— 190 S - CaCfe 1,5 3« B-78 D-78 C-2 49 175 t $93259 2 W10S ■374 57& £52 68 >y< Extatl de &Étîda + Delevure extract * EûGsktn [ALPHA-GWCANE OLIGOSACCHARIDE [□WS DERACINE DE POLYLUSMIA™™™™™™ Acid hyaiiffomgae + 4 * + Ÿ SI »" CM œ S qgg E - 5 CS DS 285 553 275 S25 1S3949 233 342 35 552 91 14 / as Estait de. MdaCCHARI yeast +■ Estait CALPHA-GLUCAKE (ET) AIS OF POLYMNIA SONCHIFODA ROOT and LACTOBACILLUSÏ * Di potassium glycyntaste* &fannsse + Acid hvateosistse 4 + + + + ,.ÿ r,j es fi “>5 'J-7” is D-1 o °. 23S 703 177 421 239 178 SS 992 103 34 ?ÎS Extract of Mds * Yeast extract + Ecosto- ( DALPHA-GLUCANE OLIGOSACCHARIDE [ET^tOS OF ROOT OF POL' Aj.p.FTp O ® § SSSG? g ® ija ü gg “S 3 s? + + + + + + BS C - 3 D-3 554934 St 7713 439 552 554GS7 3S 995 215 14 LACTOBACiLLUS] + Dipotassium giycyffhszate* Mannose * HyaJsjromgtie S-ducan acid.

[0184]

[0185]

[0186]

[0187] (1): Statistical significance threshold ns: > 0.05, Not significant *: 0.01 to 0.05, significant **: 0.001 to 0.01, Very significant

[0188] ***: < 0.001, Extremely significant Clinical protocol

[0189] - 26 women aged 26 to 64 years (average 50 years), with TEWL (water loss transepidermal) greater than or equal to 6 g. 2.h 1 on the anterior surface of the forearms.

[0190] - Application: a standardized application (2mg / cm2) of a composition according to the invention, the composition of which is detailed in Table 2, on a defined area of ​​the forearm.

[0191] - Evaluation method: TEWL measurement with a Tewameter® TM300 at T0H and T1H on treated and untreated skin.

[0192] The device allows to measure the degree of evaporation of water (representing the TEWL) on the skin surface. This TEWL is a parameter used to evaluate the quality of the barrier function.

[0193] A reduction in TEWL demonstrates the "occlusive" power of the product and its ability to retain water, which means a skin result of improved barrier function.

[0194] The results are presented in Table 6.

[0195] [Tableauxô] N=26 Baseline T1H Variation (T1H-T0H) Treated areas 7.07 + 0.86 4.57 + 1.36 -2.49+1.68 Control areas 7.22+ 1.092 6.64+ / - 1.10 -0.58 + 0.55 p-value NS (p=0.522) S (p=0.001) mean percentage improvement vs T0H -27.3%

[0196] Conclusion:

[0197] A statistically significant decrease in the TEWL Ih value is observed after a single application of the composition according to the invention: -27.3% compared to the initial measurements and the values ​​obtained on the control site.

[0198] In conclusion, the single cutaneous application of the composition according to the invention under the experimental conditions adopted, led to a statistically significant reduction in transepidermal water loss in 1 hour, showing a protective effect against water loss.

Claims

Claims

1. Cosmetic composition comprising, in a physiologically acceptable medium: - at least one microorganism of the genus Bifidobacterium and / or one of its fractions and / or one of its metabolites, - at least one yeast extract of the genus Saccharomyces, - at least one monosaccharide, preferably mannose or rhamnose, - at least one gluco-oligosaccharide (GOS), - at least one fructo-oligosaccharide (FOS), - at least one beta-glucan and / or its derivatives and / or its salts such as sodium carboxymethyl beta-glucan sodium, - at least glycyrrhizic acid and / or its salts such as di-potassium glycyrrhizate, and - at least hyaluronic acid and / or its salts.

2. Composition according to claim 1, in which at least one microorganism of the genus Bifidobacterium and / or one of its fractions and / or one of its metabolites is used in the form of a lysate.

3. Composition according to claim 1 or 2, wherein said at least one microorganism of the genus Bifidobacterium and / or one of its fractions and / or one of its metabolites is chosen from Bifidobacterium longum Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis or Bifidobacterium pseudocatenulatum and mixtures thereof.

4. Composition according to any one of the preceding claims, wherein said at least one microorganism of the genus Bifidobacterium and / or one of its fractions and / or one of its metabolites is present in a concentration of between 0.001% and 20% by dry weight, preferably between 0.001% and 15% by dry weight relative to the total weight of the composition.

5. Composition according to any one of the preceding claims, wherein said at least one yeast extract is present in a concentration of between 0.0001% and 5% by weight relative to the total weight of the composition.

6. Composition according to any one of the preceding claims, in which said at least one monosaccharide, preferably mannose or rhamnose, is present in a concentration of between 0.0001% and 20% by weight, preferably 0.001% and 10% by weight, and most preferably 0.002% and 5% by weight, relative to the total weight of the composition.

7. Composition according to any one of the preceding claims, in which said at least one gluco-oligosaccharide (GOS) is present in the composition according to the invention in a concentration of between 0.0001% and 5% by weight, preferably between 0.0002% and 2% by weight, even more preferably between 0.0005% and 1% by weight relative to the total weight of the composition.

8. Composition according to any one of the preceding claims, in which said at least one fructo-oligosaccharide (FOS) is present in the composition according to the invention in a concentration of between 0.0001% and 1% by weight, preferably between 0.00002% and 0.5%, even more preferably between 0.00003% and 0.1% by weight relative to the total weight of the composition.

9. Composition according to any one of the preceding claims, in which the mass ratio [GOS / FOS] is at least 2, preferably between 2 and 4, even better between 3 and 4.

10. Composition according to any one of the preceding claims, in which said at least one beta-glucan and / or its derivatives and / or its salts such as sodium carboxymethyl beta-glucan according to the invention will be used at a concentration of 0.0001% to 1%, preferably of 0.0002% to 0.5% and even more preferably of 0.0003% to 0.3% relative to the total weight of the composition.

11. Composition according to any one of the preceding claims, in which said at least one glycyrrhizic acid and / or its salts such as dipotassium glycyrrhizate according to the invention will be used at a concentration of 0.0001% to 2%, preferably of 0.0002% to 1.5% and even more preferably of 0.0003% to 1% relative to the total weight of the composition.

12. Use of a cosmetic composition according to any one of the preceding claims for skin care, preferably for improving the barrier function.

13. Use according to claim 12, for moisturizing the skin, improving the radiance and smoothness of the skin, and / or preventing the appearance of fine lines.

14. A cosmetic treatment method for skin care, in particular for improving the barrier function, more particularly for moisturizing the skin, improving the radiance and softness of the skin, and / or preventing the appearance of fine lines, comprising the application of a cosmetic composition according to any one of claims 1 to 11.

Images